Net Loss (USD, thousands)

Depreciation and Amortization (USD, thousands)

Stock-Based Compensation Expense (USD, thousands)

Change in Fair Value of Warrant Liabilities (USD, thousands)

Non-Cash Impairment of Licensed Technology (USD, thousands)

Non-Cash Loss/(Gain) on Operating Lease Right-of-Use Assets (USD, thousands)

Non-Cash Impairment of Construction-in-Progress (USD, thousands)

Accretion and Interest on Short-Term Investments (USD, thousands)

Amortization of Right-of-Use Lease Assets (USD, thousands)

Non-Cash Interest (USD, thousands)

Loss on Disposal of Property and Equipment (USD, thousands)

Gain on Lease Termination (USD, thousands)

Change in Accounts Receivable (USD, thousands)

Change in Other Receivables (USD, thousands)

Change in Prepaid Expenses and Other Current Assets (USD, thousands)

Change in Other Assets (USD, thousands)

Change in Accounts Payable and Accrued Expenses (USD, thousands)

Change in Lease Liabilities (USD, thousands)

Change in Payable to Licensor (USD, thousands)

Change in Other Current Liabilities (USD, thousands)

Net Cash Used in Operating Activities (USD, thousands)

Capital Expenditures (USD, thousands)

Proceeds from Disposal of Property and Equipment (USD, thousands)

Purchases of Short-Term Investments (USD, thousands)

Proceeds from Maturities of Short-Term Investments (USD, thousands)

Net Cash Provided by (Used in) Investing Activities (USD, thousands)

Proceeds from ATM Sales of Common Stock, Net of Issuance Costs (USD, thousands)

Proceeds from Sales of Common Stock Under Direct Placement Offering, Net of Issuance Costs (USD, thousands)

Proceeds from Sales of Common Stock and Warrants in Private Offering, Net of Issuance Costs (USD, thousands)

Proceeds from Net Settlement of Restricted Share Awards (USD, thousands)

Payment of Debt Issuance Cost (USD, thousands)

Proceeds from Issuance of Series A and Series B Convertible Redeemable Preferred Stock, Net of Issuance Costs (USD, thousands)

Redemption of Series A and Series B Convertible Redeemable Preferred Stock (USD, thousands)

Net Cash Provided by Financing Activities (USD, thousands)

Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash (USD, thousands)

Additions (Deletions) to Right-of-Use Lease Assets in Exchange for New or Modifications to Operating Lease Liabilities (USD, thousands)

Deletions to Operating Lease Liabilities Obtained from New Operating Lease Liabilities Resulting from Modification of Original Lease Arrangement (USD, thousands)

Change in Accounts Payable, Accrued Expenses and Lease Liabilities (USD, thousands)

Gain recognized in earnings from change in fair value (USD, thousands)

Cash, Cash Equivalents and Restricted Cash at Beginning of Year (USD, thousands)

Cash, Cash Equivalents and Restricted Cash at End of Year (USD, thousands)

Cash and Cash Equivalents (USD, thousands)

Restricted Cash (USD, thousands)

Total Cash, Cash Equivalents and Restricted Cash (USD, thousands)

1af6f1a686d7386a220677a9497d067286d5331b309325fd78c66fa1cc81d60e

License and other revenues (USD, thousands)

Royalties (USD, thousands)

Research and development (USD, thousands)

General and administrative (USD, thousands)

Gain on operating lease right-of-use assets (USD, thousands)

Total expenses (USD, thousands)

Loss from operations (USD, thousands)

Interest income (USD, thousands)

Interest expense (USD, thousands)

Change in fair value of warrant and derivative liabilities (USD, thousands)

Other income (USD, thousands)

Net loss (USD, thousands)

71bdec2545b93d8382d051ee4f2d1f2d0e63f91a284be2217b313a1d475da048

Cash and cash equivalents (USD, thousands)

Short-term investments (USD, thousands)

Restricted cash (USD, thousands)

Other receivables (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Property and equipment, net (USD, thousands)

Operating lease right-of-use assets (USD, thousands)

Other assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued expenses (USD, thousands)

Current portion of long-term debt (USD, thousands)

Current portion of operating lease liability (USD, thousands)

Current portion payable to licensor (USD, thousands)

Other current liabilities (USD, thousands)

Total current liabilities (USD, thousands)

Long-term operating lease liabilities (USD, thousands)

Long-term debt (USD, thousands)

Warrant liabilities (USD, thousands)

Total liabilities (USD, thousands)

Common stock (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated deficit (USD, thousands)

Accumulated other comprehensive loss (USD, thousands)

Total stockholders’ equity (USD, thousands)

Total liabilities and stockholders’ equity (USD, thousands)

5639295bc59fdf6ac6e63a4d3b6ac9288b3d54fc2e3373cc128ee508d2ca514f

License and other revenues

- Clinical milestone revenue

- Deferred revenue recognition

- Sublease revenue

Total Revenue

3a63e4dadbea4585bdb77905791f9e969f55f7916075136cf8d99d583297b326

Abeona Therapeutics Inc (ABEO)

Financials